

HYPERSENSITIVITY

It occurs on initial exposure or re-exposure of basiliximab.⁽¹⁾

Management:

- Therapy must be permanently discontinued and no further dose to be administered.
- Anaphylaxis with intramuscular adrenaline (epinephrine), oxygen, intravenous (IV) antihistamine, and supporting blood pressure with IV fluids.⁽²⁾

(1) Annex I. Netherlands Yearb Int Law. 1985;16:279.

(2) Vaillant AAJ, Vashisht R, Zito PM. Immediate Hypersensitivity Reactions. StatPearls [Internet]. 2021 Jun 11 [cited 2021 Nov 19]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK513315/>

